- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01190878
Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
November 18, 2021 updated by: Sun Pharmaceutical Industries Limited
A Randomized Double-masked 14-day Study to Compare the Ocular Safety, Tolerability, and Efficacy of Differing Dosing Regimens of ISV-303 to Vehicle and Xibrom™ in Post Cataract Surgery Volunteers
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-303 compared to vehicle and Xibrom™ when dosed for 2 weeks in post-cataract-surgery volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
169
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation on the day prior to study enrollment
- Meet the best corrected visual acuity score requirement
- Meet the IOP requirement
- Additional inclusion criteria also apply
Exclusion Criteria:
- Known hypersensitivity or poor tolerance to bromfenac sodium or any component of the study medications or any of the procedural medications
- Use of any ocular topical, or systemic medication that could interfere with normal lacrimation, wound healing, the test agent, or the interpretation of study results, within 1 week prior to Day of Surgery
- Additional exclusion criteria also apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ISV-303 BID
|
0.075% of bromfenac in DuraSite dosed QD
0.075% of bromfenac in DuraSite dosed BID
|
Experimental: ISV-303 QD
|
0.075% of bromfenac in DuraSite dosed QD
0.075% of bromfenac in DuraSite dosed BID
|
Active Comparator: Xibrom BID
|
0.09% bromfenac dosed BID
|
Placebo Comparator: DuraSite Vehicle BID
|
Vehicle dosed BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular Inflammation
Time Frame: 15 days
|
Anterior Chamber Cell Grade 0 at Day 15 measured on a 0 to 4 scale: "0" is 0 cells; "1" is 1-10 cells; "2" is 11-20 cells; "3" is 21-50 cells; "4" is > 50 cells.
|
15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
January 1, 2011
Study Registration Dates
First Submitted
August 26, 2010
First Submitted That Met QC Criteria
August 27, 2010
First Posted (Estimate)
August 30, 2010
Study Record Updates
Last Update Posted (Actual)
November 19, 2021
Last Update Submitted That Met QC Criteria
November 18, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-10-303-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Inflammation
-
AgnesDirection Générale de l'Offre de Soins; Laboratoires TheaRecruitingOcular Inflammation | Ocular ProsthesesFrance
-
Campus Bio-Medico UniversityCompletedOcular Inflammation | Ocular Surface DiseaseItaly
-
Laboratorios Sophia S.A de C.V.CompletedOcular Inflammation | Ocular Pain | Pterygium | Post-surgical InflammationMexico
-
Sligo General HospitalCompletedOcular InflammationIreland
-
Surface Ophthalmics, Inc.CompletedPost-surgical Ocular Inflammation | Post-surgical Ocular PainUnited States
-
Kerry Assil, MDUnknownPost-Surgical Ocular Pain | Post-Surgical Ocular InflammationUnited States
-
Tarsier PharmaCompletedPost Surgical Ocular InflammationUnited States
-
University of TriesteCompleted
-
Federal University of São PauloAllerganCompletedOcular Infection and InflammationBrazil
-
Alcon ResearchCompletedOcular Inflammation Associated With BlepharaconjunctivitisUnited States
Clinical Trials on ISV-303
-
Taiho Pharmaceutical Co., Ltd.Completed
-
Sun Pharmaceutical Industries LimitedCompleted
-
Sun Pharmaceutical Industries LimitedCompletedOcular Inflammation
-
Sun Pharmaceutical Industries LimitedCompleted
-
Alpine Immune Sciences, Inc.Completed
-
pH PharmaCompletedOtherwise Healthy Overweight or ObeseUnited States
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
pH PharmaCompletedA Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy SubjectsHealthy VolunteerUnited States
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
AbbVieRecruiting